Source:http://linkedlifedata.com/resource/pubmed/id/18515660
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
2008-12-9
|
| pubmed:abstractText |
Interleukin-21 (IL-21) is a recently described immunoregulatory cytokine. It has been identified as a very potent immunotherapeutic agent in several cancer types in animal models, and clinical studies are ongoing. IL-21 belongs to the type I cytokine family of which other members, ie, IL-2, IL-15, and IL-4, have been shown to exert activities on vascular endothelial cells (ECs). We hypothesized that IL-21, in addition to inducing the antitumor immune response, also inhibits tumor angiogenesis. In vitro experiments showed a decrease of proliferation and sprouting of activated ECs after IL-21 treatment. We found that the IL-21 receptor is expressed on vascular ECs. Furthermore, in vivo studies in the chorioallantoic membrane of the chick embryo and in mouse tumors demonstrated that IL-21 treatment disturbs vessel architecture and negatively affects vessel outgrowth. Our results also confirm the earlier suggested angiostatic potential of IL-2 in vitro and in vivo. The angiostatic effect of IL-21 is confirmed by the decrease in expression of angiogenesis-related genes. Interestingly, IL-21 treatment of ECs leads to a decrease of Stat3 phosphorylation. Our research shows that IL-21 is a very powerful antitumor compound that combines the induction of an effective antitumor immune response with inhibition of tumor angiogenesis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-21,
http://linkedlifedata.com/resource/pubmed/chemical/STAT3 Transcription Factor,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-21
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1528-0020
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
112
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4940-7
|
| pubmed:meshHeading |
pubmed-meshheading:18515660-Angiogenesis Inhibitors,
pubmed-meshheading:18515660-Animals,
pubmed-meshheading:18515660-Antineoplastic Agents,
pubmed-meshheading:18515660-Aorta,
pubmed-meshheading:18515660-Cell Line,
pubmed-meshheading:18515660-Cell Line, Tumor,
pubmed-meshheading:18515660-Cell Proliferation,
pubmed-meshheading:18515660-Chick Embryo,
pubmed-meshheading:18515660-Endothelial Cells,
pubmed-meshheading:18515660-Endothelium, Vascular,
pubmed-meshheading:18515660-Humans,
pubmed-meshheading:18515660-Interleukins,
pubmed-meshheading:18515660-Mice,
pubmed-meshheading:18515660-Neovascularization, Pathologic,
pubmed-meshheading:18515660-Neovascularization, Physiologic,
pubmed-meshheading:18515660-Phosphorylation,
pubmed-meshheading:18515660-Receptors, Interleukin-21,
pubmed-meshheading:18515660-STAT3 Transcription Factor
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Angiostatic activity of the antitumor cytokine interleukin-21.
|
| pubmed:affiliation |
Angiogenesis Laboratory, School for Oncology and Developmental Biology, Department of Pathology, Maastricht University and University Hospital, Maastricht, The Netherlands.
|
| pubmed:publicationType |
Journal Article
|